UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 248

Sortiert nach

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

PloS one, 2019-12, Vol.14 (12), p.e0220265-e0220265

2019

Volltextzugriff (PDF)

Resistance among urinary tract pathogens collected in Europe during 2018

Journal of global antimicrobial resistance., 2020-12, Vol.23, p.439-444

2020

Volltextzugriff (PDF)

Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4154-4160

2011

Volltextzugriff (PDF)

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine

Diagnostic microbiology and infectious disease, 2014-09, Vol.80 (1), p.19-25

2014

Volltextzugriff (PDF)

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2716-2719

2010

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.885-891

2014

Volltextzugriff (PDF)

Avibactam Pharmacokinetic/Pharmacodynamic Targets

Antimicrobial agents and chemotherapy, 2018-06, Vol.62 (6)

2018

Volltextzugriff (PDF)

National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study

Antimicrobial Agents and Chemotherapy, 2007-12, Vol.51 (12), p.4382-4389

2007

Volltextzugriff (PDF)

Factors Associated with Relative Rates of Antimicrobial Resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998–2002)

Clinical infectious diseases, 2003-04, Vol.36 (8), p.963-970

2003

Volltextzugriff (PDF)

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

The New England journal of medicine, 2022-04, Vol.386 (14), p.1327-1338

2022

Volltextzugriff (PDF)

In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem

Antimicrobial agents and chemotherapy, 2020-07, Vol.64 (8)

2020

Volltextzugriff (PDF)

Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST Surveillance Program, 1999–2000

Clinical infectious diseases, 2002-03, Vol.34 (Supplement-1), p.S4-S16

2002

Volltextzugriff (PDF)

Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection

Journal of antimicrobial chemotherapy, 2024-04, Vol.79 (4), p.875-882

2024

Volltextzugriff (PDF)

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Volltextzugriff (PDF)

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

Antimicrobial agents and chemotherapy, 2023-10, Vol.67 (10), p.e0053523-e0053523

2023

Volltextzugriff (PDF)

Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Antimicrobial Agents and Chemotherapy, 2008-07, Vol.52 (7), p.2639-2643

2008

Volltextzugriff (PDF)

Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis

Antimicrobial Agents and Chemotherapy, 2001-04, Vol.45 (4), p.1037-1042

2001

Volltextzugriff (PDF)

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

Journal of antimicrobial chemotherapy, 2010-11, Vol.65 (suppl-4), p.iv9-iv16

2010

Volltextzugriff (PDF)

Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

Antimicrobial Agents and Chemotherapy, 2005-10, Vol.49 (10), p.4253-4262

2005

Volltextzugriff (PDF)

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

Antimicrobial Agents and Chemotherapy, 2003-05, Vol.47 (5), p.1689-1693

2003

Volltextzugriff (PDF)

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Journal of clinical microbiology, 2018-06, Vol.56 (6)

2018

Volltextzugriff (PDF)

Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States

Antimicrobial Agents and Chemotherapy, 2003-06, Vol.47 (6), p.1790-1797

2003

Volltextzugriff (PDF)

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points

Open forum infectious diseases, 2019-04, Vol.6 (4), p.ofz149-ofz149

2019

Volltextzugriff (PDF)

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among β-Lactam Agents

Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4923-4927

2014

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(236)
Mit Volltextzugriff
(230)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(152)
Humans
(124)
Biological And Medical Sciences
(79)
Microbiology
(73)
Medical Sciences
(65)
Female
(56)
Pharmacology & Pharmacy
(54)
Pharmacology. Drug Treatments
(51)
Microbial Sensitivity Tests
(50)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(49)
Anti-Bacterial Agents - Pharmacology
(46)
Infectious Diseases
(45)
Antibacterial Agents
(33)
Adult
(31)
Middle Aged
(29)
Streptococcus Pneumoniae
(26)
Streptococcus Pneumoniae - Drug Effects
(26)
Animals
(24)
Fundamental And Applied Biological Sciences. Psychology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

Resistance among urinary tract pathogens collected in Europe during 2018

Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Avibactam Pharmacokinetic/Pharmacodynamic Targets

National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study

Factors Associated with Relative Rates of Antimicrobial Resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998–2002)

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem

Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST Surveillance Program, 1999–2000

Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among β-Lactam Agents

Suchergebnisse filtern